Zenith Capital Corp. (ZHCLF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -8.6 Million USD | 21.51% |
| 2022 | -10.96 Million USD | -152474.45% |
| 2021 | -7.18 Million USD | -9.11% |
| 2020 | -6.58 Million USD | 27.97% |
| 2019 | -9.14 Million USD | 15.97% |
| 2018 | -10.88 Million USD | 99.88% |
| 2017 | -9.25 Million USD | -20.59% |
| 2016 | -7.67 Million USD | 5.46% |
| 2015 | -8.12 Million USD | 32.94% |
| 2014 | -12.1 Million USD | 25.79% |
| 2013 | -16.31 Million USD | -53.8% |
| 2012 | -10.6 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.34 Million USD | -18.45% |
| 2023 Q4 | -1.13 Million USD | 39.51% |
| 2023 Q2 | -2.63 Million USD | 10.94% |
| 2023 Q1 | -2.96 Million USD | 52.36% |
| 2023 Q3 | -1.87 Million USD | 29.0% |
| 2022 Q3 | -1446.00 USD | 32.37% |
| 2022 Q1 | -1163.00 USD | 99.92% |
| 2022 FY | - USD | -152474.45% |
| 2022 Q2 | -2138.00 USD | -83.83% |
| 2022 Q4 | -6.21 Million USD | -429844.67% |
| 2021 Q4 | -1.44 Million USD | 21.34% |
| 2021 Q1 | -2.04 Million USD | -24.91% |
| 2021 Q2 | -1.87 Million USD | 8.28% |
| 2021 Q3 | -1.83 Million USD | 2.14% |
| 2021 FY | - USD | -9.11% |
| 2020 Q2 | -1.72 Million USD | -12.04% |
| 2020 FY | - USD | 27.97% |
| 2020 Q3 | -1.69 Million USD | 1.68% |
| 2020 Q4 | -1.63 Million USD | 3.48% |
| 2020 Q1 | -1.53 Million USD | 28.38% |
| 2019 Q1 | -2.48 Million USD | 37.02% |
| 2019 FY | - USD | 15.97% |
| 2019 Q4 | -2.14 Million USD | 24.04% |
| 2019 Q3 | -2.82 Million USD | -67.46% |
| 2019 Q2 | -1.68 Million USD | 32.11% |
| 2018 Q4 | -3.94 Million USD | -56.65% |
| 2018 FY | - USD | 99.88% |
| 2018 Q3 | -2.51 Million USD | -6.06% |
| 2018 Q2 | -2.37 Million USD | -16.36% |
| 2018 Q1 | -2.04 Million USD | 24.27% |
| 2017 Q2 | -1.8 Million USD | 19.92% |
| 2017 Q3 | -2.5 Million USD | -38.89% |
| 2017 Q1 | -2.25 Million USD | 0.04% |
| 2017 FY | - USD | -20.59% |
| 2017 Q4 | -2.69 Million USD | -7.5% |
| 2016 FY | - USD | 5.46% |
| 2016 Q4 | -2.25 Million USD | -29.08% |
| 2016 Q3 | -1.74 Million USD | 4.59% |
| 2016 Q2 | -1.83 Million USD | 0.7% |
| 2016 Q1 | -1.84 Million USD | 14.43% |
| 2015 FY | - USD | 32.94% |
| 2015 Q1 | -2.06 Million USD | 4.08% |
| 2015 Q4 | -2.15 Million USD | -25.95% |
| 2015 Q3 | -1.71 Million USD | 21.66% |
| 2015 Q2 | -2.18 Million USD | -5.56% |
| 2014 Q4 | -2.15 Million USD | 1.42% |
| 2014 Q1 | -4.23 Million USD | 9.39% |
| 2014 FY | - USD | 25.79% |
| 2014 Q3 | -2.18 Million USD | 30.41% |
| 2014 Q2 | -3.14 Million USD | 25.81% |
| 2013 Q2 | -3.4 Million USD | 26.01% |
| 2013 Q3 | -3.64 Million USD | -7.15% |
| 2013 Q4 | -4.67 Million USD | -28.38% |
| 2013 Q1 | -4.59 Million USD | -42.0% |
| 2013 FY | - USD | -53.8% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | -3.23 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 87.885% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -45.153% |
| SQZ Biotechnologies Company | -64.14 Million USD | 86.583% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 50.455% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 109.152% |
| Mesoblast Limited | -62.38 Million USD | 86.206% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -460.269% |
| Genus plc | 73.7 Million USD | 111.677% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -30.167% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -142.628% |
| Marizyme, Inc. | -34.28 Million USD | 74.896% |
| ContraFect Corporation | -64.99 Million USD | 86.76% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 1.892% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -90.138% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -513.921% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -225.437% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -270.338% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1561.242% |
| Accustem Sciences Inc. | -3.74 Million USD | -129.713% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 82.155% |
| EV Biologics, Inc. | -1.26 Million USD | -579.172% |
| Q BioMed Inc. | -617.62 Thousand USD | -1293.395% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 340.929% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1260.835% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -276.714% |
| Biomind Labs Inc. | -1.03 Million USD | -731.86% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 187.132% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -20.174% |
| Skye Bioscience, Inc. | -13.54 Million USD | 36.476% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -478.589% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -34324.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -121.557% |
| IMV Inc. | -35.52 Million USD | 75.774% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 45.771% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -243.97% |
| GB Sciences, Inc. | -1.41 Million USD | -506.105% |
| Alpha Cognition Inc. | -9.7 Million USD | 11.33% |
| HST Global, Inc. | -5303.00 USD | -162185.499% |
| CSL Limited | 4.78 Billion USD | 100.18% |
| Halberd Corporation | -74.27 Thousand USD | -11486.047% |
| Enzolytics Inc. | -2.12 Million USD | -305.555% |
| Resverlogix Corp. | -11.74 Million USD | 26.708% |
| Affymax, Inc. | -14.29 Million USD | 39.797% |
| SYBLEU INC | -141.57 Thousand USD | -5978.929% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -180.965% |
| argenx SE | -216.02 Million USD | 96.016% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 84.449% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 807.149% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -474.152% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 2371.647% |
| AVAX Technologies, Inc. | -6.11 Million USD | -40.79% |
| Genscript Biotech Corporation | -248.71 Million USD | 96.54% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -49300.149% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -251.773% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -4789.096% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 78.288% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -197.546% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -722.508% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 128089.292% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -391.772% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -348.017% |
| BioStem Technologies, Inc. | -7.55 Million USD | -13.932% |
| ONE Bio Corp. | 13.61 Million USD | 163.219% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -4652.386% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -318.376% |
| Agentix Corp. | -1.37 Million USD | -527.371% |
| LadRx Corporation | 412.28 Thousand USD | 2187.401% |
| Cell Source, Inc. | -4.27 Million USD | -101.427% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -2243.548% |
| Regen BioPharma, Inc. | 1.46 Million USD | 687.057% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -818.513% |
| NovAccess Global Inc. | -1.03 Million USD | -731.661% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 197.201% |
| Itoco Inc. | -1.86 Million USD | -360.461% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -2167.004% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -671.147% |
| Kadimastem Ltd | -2.62 Million USD | -227.925% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -3498.578% |
| CytoDyn Inc. | -18.02 Million USD | 52.266% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -10789.673% |
| Mobile Lads Corp. | -2.24 Million USD | -283.998% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -70273.702% |
| Qrons Inc. | -40.08 Thousand USD | -21371.52% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1671.956% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1731.676% |
| Rebus Holdings, Inc. | -951 Thousand USD | -804.942% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -710.35% |
| International Stem Cell Corporation | 202 Thousand USD | 4360.396% |
| Bioxytran, Inc. | -3.82 Million USD | -125.279% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -16248.784% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -249.563% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 76.007% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -19024.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -214.317% |
| Neutra Corp. | -181.24 Thousand USD | -4648.217% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 57.309% |
| PureTech Health plc | -11.62 Million USD | 25.983% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 57.306% |
| IXICO plc | -707 Thousand USD | -1117.256% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -11.984% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 82.199% |
| CSL Limited | 4.73 Billion USD | 100.182% |
| Cellectis S.A. | -92.63 Million USD | 90.71% |